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Abstract
Background: Repeated use, coitus-independent microbicide gels that do not contain antiretroviral agents also used as first
line HIV therapy are urgently needed to curb HIV spread. Current formulations require high doses (millimolar range) of
antiretroviral drugs and typically only provide short-term protection in macaques. We used the macaque model to test the
efficacy of a novel combination microbicide gel containing zinc acetate and micromolar doses of the novel non-nucleoside
reverse transcriptase inhibitor MIV-150 for up to 24 h after repeated gel application.
Methods and Findings: Rhesus macaques were vaginally challenged with SHIV-RT up to 24 h after repeated administration
of microbicide versus placebo gels. Infection status was determined by measuring virologic and immunologic parameters.
Combination microbicide gels containing 14 mM zinc acetate dihydrate and 50 mM MIV-150 afforded full protection (21 of
21 animals) for up to 24 h after 2 weeks of daily application. Partial protection was achieved with the MIV-150 gel (56% of
control at 8 h after last application, 11% at 24 h), while the zinc acetate gel afforded more pronounced protection (67% at
8–24 h). Marked protection persisted when the zinc acetate or MIV-150/zinc acetate gels were applied every other day for 4
weeks prior to challenge 24 h after the last gel was administered (11 of 14 protected). More MIV-150 was associated with
cervical tissue 8 h after daily dosing of MIV-150/zinc acetate versus MIV-150, while comparable MIV-150 levels were
associated with vaginal tissues and at 24 h.
Conclusions: A combination MIV-150/zinc acetate gel and a zinc acetate gel provide significant protection against SHIV-RT
infection for up to 24 h. This represents a novel advancement, identifying microbicides that do not contain anti-viral agents
used to treat HIV infection and which can be used repeatedly and independently of coitus, and underscores the need for
future clinical testing of their safety and ability to prevent HIV transmission in humans.
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Introduction
There is a critical need for safe and effective microbicides that
women worldwide can use repeatedly and independently from the
time of coitus, to prevent sexual transmission of human
immunodeficiency virus (HIV) and other sexually transmitted
infections (STIs). While promising, candidate microbicide gels
containing agents that act on specific viral targets and/or
antagonists of cell-virus interactions typically require mM or
mg/ml amounts of the drug to significantly protect against
mucosal infection with immunodeficiency virus in macaques
[1,2,3,4,5,6,7]. Notably, the 1% (1 mg/ml) tenofovir gel that
protected macaques against repeated vaginal infection when given
30 min prior to each challenge [5], was shown to be effective in
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12 h before and no more than 12 h after intercourse in the
CAPRISA 004 trial [8]. This provides the first proof of concept
that topical microbicides can limit HIV spread in humans and that
this was predicted from the macaque studies.
In microbicides it is preferable to avoid first line anti-HIV
agents that are used to treat HIV-infected people, or agents with
the potential to induce class- or cross-resistance to them [9,10].
There was no evidence of tenofovir resistance in those individuals
who became infected in the CAPRISA 004 trial [8]. However,
tenofovir is used to treat HIV infection [11], therefore increasing
the chances of the transmission of tenofovir resistant viruses in the
future. An additional attribute that will increase the success of a
microbicide formulation is the ability to exhibit long lasting
protection that would allow gels to be used independently of
intercourse and thus be useful in real-world settings. Therefore,
identifying a formulation that (i) contains agents that are active
against viruses already resistant to drugs in clinical use and (ii)
provides protection when applied independent of intercourse is
vital.
We explored the use of MIV-150, a novel non-nucleoside
reverse transcriptase inhibitor (NNRTI) that is not used in current
HIV therapies, combined with zinc acetate and formulated in
carrageenan. NNRTIs are non-competitive inhibitors of RT.
Carrageenan alone (CarraguardH; 95% lambda and 5% kappa
carrageenan) was not effective at preventing HIV infection in
women [12], but the intrinsic rheological properties [13], stability,
acceptability, and safety of a carrageenan-based gel [12,14,15,
16,17,18,19] make it a useful vehicle to deliver anti-HIV drugs.
MIV-150 is a novel, potent NNRTI, which binds tightly to the
HIV reverse transcriptase (RT), and has strong antiviral (IC50 of
,1 nM) and potentially virucidal (IC50 of 400 nM) activity against
R5 and X4 viruses [13,20,21]. Moreover, MIV-150 possesses a
favorable resistance profile: it is effective against HIV-1 harboring
common single mutations in the RT gene, requires two-to-three
mutations (L100I, K103N, Y181C) to increase the IC50.10-fold,
and takes about twice as long to select HIV-1 resistance in vitro
compared to other NNRTIs like Nevirapine and Efavirenz
(Ferna ´ndez-Romero unpublished). Notably, the L100I/K103N
double mutant resistant to Efavirenz had reduced susceptibility to
MIV-150. The IC50 of MIV-150 against this double mutant
(0.9 mM vs 0.7 nM against wild type) remained at least 10-fold less
than that of Efavirenz (.10 mM vs 0.6 nM against wild type).
However, the Y181C mutant resistant to Nevirapine remained
fully sensitive to MIV-150 (0.2 nM vs 0.7 nM against wild type).
Importantly, MIV-150 also possesses a potent memory effect, since
cells exposed to MIV-150 in vitro remain resistant to infection for
up to 5 d (Ferna ´ndez-Romero unpublished).
Formulating MIV-150 in a carrageenan gel has yielded
encouraging results to date. In vitro studies demonstrated the
additive effects of MIV-150 and carrageenan [13]. MIV-150 also
prevented dendritic cell (DC)-facilitated infection of CD4
+ T cells
at nM concentrations [20]. In addition, in vivo efficacy of 500 mM
MIV-150 in carrageenan was confirmed against our chimeric
SHIV-RT (SIVmac239 with HIV-1 RT) when applied topically
30 min prior to vaginal challenge of either naı ¨ve or HSV-2
infected macaques, despite the increased susceptibility to SHIV-
RT infection of the latter [20,22].
In vitro studies suggest that zinc salts have activity against HIV as
well as other viruses, including HSV-2 [23,24,25], infection with
which has been shown to facilitate HIV transmission [26,27,28].
However, documentation of anti-viral activity in vitro is compli-
cated by the toxicity of zinc in many cell-based assays,
underscoring the need to conduct in vivo studies of zinc’s anti-
viral activity. Moreover, we found that zinc acetate delivered in
carrageenan (but not zinc acetate in solution or in the
hydroxyethyl cellulose placebo) protects mice against high dose
vaginal challenge with HSV-2 (Ferna ´ndez-Romero, unpublished).
Thus, gels containing zinc acetate represent a promising approach
to impede HIV transmission both directly by virtue of anti-HIV
activity, and indirectly by reducing other STIs. In addition, since
condom use might be reduced upon introduction of a microbicide
[29], a formulation that targets HIV as well as other STIs, like
HSV-2, is especially desirable.
To assess the potential of a novel antiretroviral/zinc combination
microbicide in a manner designed to simulate how women will use
gels, we evaluated the anti-viral efficacy of repeated vaginal
application of MIV-150 and zinc acetate in a macaque vaginal
challenge model. Herein we show that daily usage of gels containing
low dose MIV-150 (50 mM) afforded .50% protection from
infection for up to 8 h after 2 weeks of daily application, and that
zinc acetate alone protected .65% of macaques from infection for
up to 24 h.Notably, the combination of low dose MIV-150 and zinc
acetateprovidedcompleteprotectionfrominfectionforatleast24 h.
Both zinc acetate alone and the MIV-150/zinc acetate combination
gels still markedly reduced infection when applied every other day.
These data will advance the development of coitally-independent
combination microbicide gels to limit HIV spread.
Methods
Ethics Statement
Adult female Chinese rhesus macaques (Macaca mulatta) were
housed and cared for in compliance with the regulations under the
Animal Welfare Act, the Guide for the Care and Use of Laboratory
Animals, at Tulane National Primate Research Center (TNPRC;
Covington, LA). Animals were monitored continuously by veteri-
narians to ensure their welfare. Veterinarians at the TNPRC
Division of Veterinary Medicine have established procedures to
minimize pain and distress through several means. Monkeys were
anesthetized with ketamine-HCl (10 mg/kg) or tiletamine/zolaze-
pam (6 mg/kg) prior to all procedures. Preemptive and post
procedural analgesia (buprenorphine 0.01 mg/kg) was required for
procedures that would likely cause more than momentary pain or
distress in humans undergoing the same procedures. The above
listed anesthetics and analgesics were used to minimize pain or
distress associated with this study in accordance with the
recommendations of the Weatherall Report. Any sick animals were
euthanized using methods consistent with recommendations of the
American Veterinary Medical Association (AVMA) Panel on
Euthanasia. All studies were approved by the Animal Care and
Use Committee of the TNPRC (OLAW assurance #A4499-01)
and in compliance with animal care procedures. TNPRC is
accredited by the Association for Assessment and Accreditation of
Laboratory Animal Care (AAALAC#000594).
Animal treatments and challenge
Animals tested negative for simian type D retroviruses, simian T
cell leukemia virus-1, and SIV prior to use in the efficacy studies.
The animals were sexually mature (ranging from 4–12 years old)
and their weights ranged from 4–10 kg. There was no evidence of
a correlation between an animal’s age at the time of challenge and
infection status. Uninfected and healthy SHIV-RT infected
animals available from completed microbicide studies were used
for the PK and biomarker studies. All blood (no more than 10 ml/
kg/month), fluids, and superficial lymph node biopsies were
transported overnight from the TNPRC to our laboratories in
New York by overnight courier service for processing and analysis.
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30 mg i.m. injection of Depo-Provera to thin the vaginal epithelium
as well to control cycling [30]. At the designated times, single 3 ml
applications or repeated 2 ml applications of microbicide candidate
gel (versus the vehicle carrageenan and methyl cellulose [MC]
controls) were applied atraumatically into the vaginal vault with a
pliable pediatric feeding tube either before or after challenge with
0.5 ml (for repeated gel treated animals) or 1 ml (for animals
receiving one gel dose) of 10
3 TCID50 SHIV-RT (SIVmac239 and
HIV-1hxb2RT). A supineposition wasmaintained for all animals,to
allow absorption of virus for 20 min post challenge. There was no
evidence of leakage from the animals. Control gel-treated animals
were included with every challenge. The infection frequencies for
animals treated at different times with the MC placebo were
comparable and so those data have been pooled to provide the MC
dataset. This wasalsothe case for animals treatedwith carrageenan.
Individual animal information is summarized in Tables S1–S3. For
the PK/biomarker studies the animals were treated with Depo-
Provera prior to gel treatment just as in the efficacy studies, but
without the virus challenge.
Virus stock
The original SHIV-RT stocks were grown in PHA-activated
human peripheral blood mononuclear cells (PBMCs) (kindly
provided by Disa Bo ¨ttiger, Medivir AB, Sweden). A subsequent
stock was generated from this in PHA-activated macaque PBMCs.
Stocks were re-titered using the 174xCEM cell line (NIH AIDS
Research & Reference Reagent Program), and TCID50 values
were calculated using the Reed and Muench formula. Both stocks
infect with comparable frequency in vivo.
Microbicide formulations
The 2.5% (w/w) MC placebo gels (Lot numbers 32805, 110205,
032807, 011008, 080602A2005SR, 080804A2005MR, 09021-
7A2005MR, 090610A2005MR) (Fisher) and the 3% (w/w)
carrageenan vehicle PC-515 (Lot numbers 32805, 010908,
080805A515SR, 090127A515SR, 090612A515MR) were used as
controls [31]. MC was originally used to parallel the human studies
testing Carraguard where MC was the placebo [12] and to rule out
any barrier effect of the carrageenan vehicle as was observed in our
earlier macaque studies [20]. PC-817 (Lot numbers 32805, 011508,
032707-A, 080603A817MR, 080811A817MR, and 090210A81-
7MR) and PC-815 (Lot numbers 080807A815SR, 09020-
9A815MR, 090609A815MR) contained 3% (w/w) carrageenan,
either 500 mM (PC-817) or 50 mM (PC-815) MIV-150, and 1%
DMSO (Sigma, St. Louis, MO). PC-1005 (Lot numbers 0806-
04A1005MR, 080810A1005SR, 090205A1005MR, 100126A10-
05MR) contained 3% (w/w) carrageenan, 50 mM MIV-150,
14 mM zinc acetate dihydrate, and 1% DMSO. PC-707 (Lot
numbers 090202A707MR, 090204A707MR, 100127A707MR)
contained 3% (w/w) carrageenan and 14 mM zinc acetate
dihydrate. Gels were stored at room temperature and used for the
studies within 7–28 days of formulation. Gel viscosity and anti-HIV
activity were verified for each Lot prior to in vivo use. The pH of the
gels was buffered to 6.860.2 in the final manufacturing step, so any
change in pH due to the addition of zinc acetate was neutralized.
MIV-150 was developed by Medivir AB (Sweden) and licensed to
the Population Council for development as a microbicide.
Cell isolation and sample collection
PBMCs were isolated from EDTA blood using Ficoll-Hypaque
density gradient centrifugation (Amersham Pharmacia Biotech,
Uppsala, Sweden) as already described [32]. RPMI 1640
(Invitrogen/GIBCO, Carlsbad, CA, USA) culture medium
containing 2 mM L-glutamine (Invitrogen/GIBCO) 10 mM
HEPES (N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid)
(Invitrogen/GIBCO), 50 mM 2-mercaptoethanol (Sigma) penicil-
lin (100 U/ml) and streptomycin (100 mg/ml) (Invitrogen/
GIBCO) and 1% heparinized human plasma (Innovative
Research, Southfield, MI) was used for final re-suspension of
PBMCs. Medium with 10% HI-FBS (heat inactivated fetal bovine
serum) (Invitrogen/GIBCO) instead of 1% human plasma was
used for the PBMC-174xCEM co-cultures. DNA was isolated
from lymph nodes as described with the DNeasyH Blood & Tissue
Kit (Qiagen Sciences, MD USA). DNA was eluted in 50 ml
RNAse/DNAse free water (Invitrogen/GIBCO). Vaginal swabs
and plasma were collected as previously described [22]. Vaginal
pH was determined by inserting pH-indicator strip (EMO
Chemical Inc., Gibbstown, NJ) into the vaginal vault for 5
minutes to saturate the pH paper with vaginal fluid.
Virus detection
Plasma viral RNA copy numbers were determined by
quantitative RT-PCR as previously reported [33]. The 6 animals
with blips were further tested by quantitative SIV gag PCR for viral
DNA levels in lymph node biopsies taken 30–57 weeks post
challenge [34].
Immune parameters
SIV-specific IFN-c T cell responses were monitored by
ELISPOT using AT-2 SIV (versus the no virus microvesicle
controls) as the stimuli [35] and SIV-specific antibodies by ELISA
[36]. Antibody positivity was defined as having positive OD values
above background baseline samples at 4–8 weeks post challenge
and IFN-c positivity was defined by at least 50 SIV-specific IFNc
spot forming cells (SFCs) per 10
6 PBMCs on more than one time
point post challenge. Cell-free vaginal fluids were analyzed for
chemokine and cytokine expression using the monkey-reactive
Beadlyte human 14-plex Detection System according to the
manufacturer’s instructions (Invitrogen). This assay recognized the
macaque IL1-b, CXCL10, IL-6, CCL5, CCL3, GM-SCF, CCL4,
CCL2, IFN-c, TNF-a, IL-3, IL-2, IL-4, CXCL8. The Luminex
200 (Luminex, Austin, TX) and StarStation softwares (Applied
Cytometry Systems, Sacramento, CA) were used to analyze
samples.
MIV-150 Radioimmunoassay (RIA)
Plasma and vaginal swabs were treated for 30 min at room
temperature with NP40 at a final concentration of 1% to
inactivate any infectious agent. The samples were stored at
280uC until the RIA was performed. The RIA for MIV-150 was
an indirect extraction based assay adapted from Kumar et al [37].
MIV-150 [38] was synthesized by catalyzed exchange with tritium
gas and purified by preparative HPLC (American Radiolabeled
Chemicals, Inc., St. Louis, MO) and a rabbit polyclonal Ab
against MIV-150 was custom prepared by Pacific Immunology
Corp. (Ramona, CA). The assay was optimized and validated for
detection of MIV-150 in plasma, vaginal swabs, and cervical/
vaginal tissues with a level of sensitivity of 2.7 nM (Rodriguez,
unpublished). MIV-150 concentration in the samples was
calculated by interpolation with the standard curve using a curve
fitting procedure (logistic 4-parameter model).
Cloning and sequencing SHIV-RT genes
Viral RNA was extracted from 1 ml aliquots of plasma from
infected animals, using the Qiagen Viral RNA Isolation Kit
(Qiagen, Valencia CA, USA) according to the manufacturer’s
Combination Gel Blocks Vaginal Infection
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(Invitrogen). A PBS control was run in parallel to ensure lack of
contaminating RNA. Viral RNA was transcribed into cDNA with
the Superscript III Reverse Transcriptase Kit (Invitrogen). RT
genes in viral cDNA were amplified by PCR, using Pfu Ultra II
Hotstart Polymerase (Agilent Technologies, Santa Clara, CA) and
primers RT amp 59 (59 upstream of HIV RT, within SIV pol,5 -
TACTAAAGAATACAAAAATGTAGA-3), and RT amp 39 (39
downstream of RT 5-CTCTGTGGATTGTATGGTACCCC-3).
Due to the lower RNA viral load, an additional nested PCR
reaction was performed for animal IE83 with primers 5-
TAAATTTTCCCATTAGCCC-3 and 5-TCTTCTGTTAGT-
GGTATTA-3. PCR amplifications were carried out using the
MyCycler Thermal Cycler (Bio-Rad, Laboratories, Inc., Hercules,
CA). After activation of the Taq polymerase at 94uC for 5 min,
DNA was amplified for 30 cycles, each at 94uC for 1 min, 44uC
for 1 min, 72uC for 2 min, with a final extension at 72uC for
5 min. Unincorporated nucleotides were removed from the PCR
product with the QIAquick PCR purification kit (Qiagen). PCR
products were ligated using the TOPO TA cloning kit (Invitrogen)
and colony miniprep DNA was prepared for sequencing
(GeneWiz, Inc., South Plainfield, NJ). DNAStar Lasergene 8
software was used to analyze sequences.
Statistical Analyses
The Fisher’s exact test was used for statistical comparison of the
percentage of SHIV-RT infected animals in the differently treated
groups. (GraphPad Prism version 5.02 for Windows, GraphPad
Software, San Diego, CA). P values ,0.05 were taken as
statistically significant.
Results
Repeated application of low dose MIV-150 and zinc
acetate combination gel prevents vaginal infection by
SHIV-RT
In previous studies we demonstrated the ability of a 500 mM
(185 mg/ml) MIV-150-containing gel to limit vaginal infection
when a single dose was applied 30 min prior to SHIV-RT
challenge of healthy [20] and HSV-2-infected [22] macaques. In
this report we confirmed that there was a trend towards protection
for up to 4 h (14% infection compared to 56% infection in the
placebo MC-treated animals; p,0.09), but any protection was lost
after 24 h, and post-exposure treatment was ineffective (Fig. 1 and
Table S1).
We then determined if a 10-fold lower dose of MIV-150 (50 mM
or 18.5 mg/ml) could be used under a repeated gel-dosing regimen
to afford longer lasting protection. Gels were applied daily for 2
weeks, and animals were challenged up to 24 h after the last
application. This protocol was intended to model real-world
topical gel application by women who would use it on a repeated
basis and independently of coitus. Furthermore, this study design
would evaluate any detrimental effects of repeated gel exposure.
When infected, animals exhibited characteristic viremia with mean
peak levels of 2.3610
6 RNA copies/ml (typically) at 2–3 weeks
post challenge, with mean set point viral loads of 1.7610
4 RNA
copies/ml being reached by week 8 (across all groups; n=37).
Otherwise, protected animals had no detectable viral RNA for up
to 20 weeks of follow-up (,30 copies/ml; n=56). In six animals,
stochastic plasma virus RNA was detected on one or two occasions
(blips; confirmed upon repeated testing), but they were otherwise
negative for all other time points examined and none of them
developed SIV-specific antibody or T cell responses (Tables S2
and S3). Furthermore, no SIV gag DNA was detected in the lymph
nodes of the six animals with blips (data not shown). Such blips in
plasma virus might reflect controlled or aborted infections, as have
been reported [39,40,41,42,43,44]. Since blips occurred across the
different treatment groups, comparisons have been made based on
the frequency of animals with typical viremia (not protected)
versus those with undetectable virus or virus blips (protected). A
MC placebo group was included to control for the non-specific
barrier effect of carrageenan that was previously observed when
animals were challenged only 30 min after a single gel application
[20]. Relative to the MC controls, the barrier effect of the
carrageenan vehicle was modest and not statistically significant in
this repeated application study, where animals were challenged 8–
24 h after the last gel application. Therefore, the protective
efficacy has been calculated as the percentage of protection of test
gels compared to carrageenan vehicle control (Fig. 2A and
Table 1).
Surprisingly, higher doses of MIV-150 offered no protective
advantage, with repeated application of the 50 mM MIV-150 gel
protecting animals by 56% and 500 mM by 33% relative to vehicle
control at the 8 h time point (Fig. 2A and Fig. S1). However,
50 mM MIV-150 afforded no significant protection relative to the
vehicle-treated animals and any protective activity of 50 mM MIV-
150 was gone after 24 h (Fig. 2A and Table 1).
We next investigated whether adding 14 mM zinc acetate
dihydrate, a concentration, which efficiently prevents vaginal and
rectal HSV-2 infection in mice (Ferna ´ndez-Romero, unpublished),
would improve protection. Zinc acetate alone provided marked
protection against SHIV-RT infection (11 of 14 protected, 67%,
p,0.06; Fig. 2A and Table 1). Strikingly, the combination of zinc
acetate and 50 mM MIV-150 in carrageenan provided full
protection for up to 24 h (p,0.0001; Fig. 2A, Table 1, and Fig.
S2). In total, 21 of 21 animals, which received MIV-150/zinc
acetate gel, were protected from vaginal SHIV-RT infection.
In order to determine whether daily gel use was required for
efficacy, we tested the activity of the two most protective gels,
MIV-150/zinc acetate and zinc acetate alone, when applied every
other day for 4 weeks, followed by virus challenge 24 h after the
last gel. This way, the animals received the same number of total
applications as those treated daily for 2 weeks, only over twice the
length of time. Both test gels provided protection after every other
day administration, but the complete protection seen with the
MIV-150/zinc acetate combination after daily treatment was lost
(Fig. 2B, Table 1, and Table S3). While we were unable to include
the carrageenan vehicle controls for this every other day regimen,
comparison to the daily-applied carrageenan control group, in
which a greater non-specific barrier effect would be expected than
for an every other day dosing regimen, revealed marked protection
(67%, 11 of 14 protected; zinc acetate and MIV-150/zinc acetate
data combined, p,0.06). Interestingly, when the data from all
animals treated with zinc acetate alone were pooled, the protection
by zinc acetate was significant (70%, 17 of 21 protected; daily and
every other day zinc acetate; p,0.02).
Using a separate group of animals, we also verified that there
were no detectable local adverse effects that could explain the
differences between the groups of animals repeatedly treated with
the zinc and/or MIV-150-containing gels. Vaginal pH and the
levels of cytokines and chemokines in fluids were measured before,
during and 8 or 24 h after a 2 week administration of the test
versus control gels. The presence of zinc acetate or MIV-150 in
the formulations had no impact on vaginal pH (Fig. S3A). Low-
level CXCL8 and CCL2 responses were detected after exposure to
carageenan, although there was no cumulative effect of repeated
application (Fig. S3B). While the levels varied between animals
(and not all animals responded), inclusion of MIV-150, zinc
Combination Gel Blocks Vaginal Infection
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formulations had no further impact on the CXCL8 and CCL2
levels (Fig. S3B). Of the factors measured, no other cytokine/
chemokines were detected in the vaginal fluids of any of the
animals tested over time (not shown).
Cervix-associated MIV-150 predicts efficacy better than
plasma or vaginal tissue MIV-150 levels
In a separate set of animals we used RIA to determine the levels
of MIV-150 within plasma, vaginal fluids, and vaginal and cervical
tissues as a measure of potential systemic absorption and
accumulation. Samples were taken after repeated treatment with
50 mM MIV-150 alone (daily) or 50 mM MIV-150 with zinc
acetate (daily versus every other day). MIV-150 was undetectable
in plasma 8 or 24 h after 2 weeks of daily or 24 h after 4 weeks of
every other day treatment with either gel, but it was detected in the
vaginal swabs (Fig. 3A). While swab MIV-150 levels were lower
24 h after daily MIV-150 treatment than daily MIV-150/zinc
acetate treatment (not statistically significant), comparable levels
were detected after every other day dosing with MIV-150/zinc
acetate. In order to determine if MIV-150 was being absorbed
systemically, followed by rapid clearance, as observed in rats
(Rodriguez unpublished), blood samples collected 0.5, 1, 4, 8, and
24 h after daily gel application were tested. MIV-150 remained
undetectable at all of these time points after application of either
50 mM MIV-150 alone or MIV-150 and zinc acetate (not shown).
Significantly more MIV-150 was present in the swabs (but not
blood) after application of the gel containing 500 mM MIV-150
compared to when the 50 mM MIV-150 gel was applied (Fig.
S4A). Interestingly, higher amounts of MIV-150 were associated
with the cervical tissues 8 h (but not 24 h) after the last (daily) dose
of the MIV-150/zinc acetate gel compared to daily dosing of
50 mM MIV-150 alone or every other day dosing of MIV-150/
zinc acetate (Fig. 3B). Concentrations associated with the vaginal
tissues were comparable 8 h after the last application of the MIV-
150/zinc acetate or MIV-150 gels, and even higher in the MIV-
150-treated animals at the 24 h time point. In animals treated with
500 mM MIV-150 much more MIV-150 was associated with
vaginal tissues and comparable levels were associated with the
cervical tissues (compared to the 50 mM MIV-150-treated animals;
Fig. S4B).
Figure 1. A single dose of 500 mM MIV-150 partially protects against vaginal SHIV-RT infection. A. 500 mM MIV-150 in carrageenan (PC-
817) or MC placebo were administered 24 or 4 h prior to (Pre) or 1 h or 4 h after (Post) challenge with 10
3 TCID50 SHIV-RT. The number of animals in
each treatment group is indicated and animals treated with MC at any time are pooled into one dataset. Plasma viral loads (SIV RNA copies/ml of
plasma) were measured over time and each symbol denotes an individual animal. B. The percentages of animals infected in each group are
summarized.
doi:10.1371/journal.pone.0015835.g001
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PLoS ONE | www.plosone.org 5 January 2011 | Volume 6 | Issue 1 | e15835Figure 2. Repeated daily application of 50 mM MIV-150/zinc acetate protects fully for at least 24 h. A. Animals were treated daily for 2
weeks with either MC placebo, carrageenan vehicle (PC-515), or carrageenan gel containing 50 mM MIV-150 (PC-815), 14 mM zinc acetate dihydrate
(PC-707), or 50 mM MIV-150/14 mM zinc acetate dihydrate (PC-1005). SHIV-RT was then applied vaginally 8 or 24 h after the last gel. The data within
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infection with drug resistant viruses
Infections occurring in the presence of MIV-150 (observed after
daily MIV-150 or every other day MIV-150/zinc acetate
treatment) might reflect the selection of drug resistant variants or
simply failure of the drug to prevent wild type virus infection. To
determine if MIV-150 had selected for drug resistant variants
present in the inocula infecting these animals, we sequenced the
RT gene of viral RNA isolated from plasma at peak viremia. As in
the controls, the RT gene sequences from infected animals that
received MIV-150 (with or without zinc acetate) were wild type
(Table S4). There were no amino acid changes at positions that
confer resistance to NNRTIs [45,46,47]. Therefore, infections
occurring in the presence of low doses of MIV-150 were not due to
the selection of drug resistant variants.
Discussion
Effective microbicides that can be used frequently and indepen-
dently of coitus are urgently needed to curb HIV spread worldwide.
Although there have been candidate microbicides showing promise
in macaques, most required mM or mg/ml amounts of the HIV-
targeting anti-viral drugs and delivery was required within minutes
or a few hours before the time of virus exposure [1,2,3,4,5,6,7]. Of
note, the 1% tenofovir gel that protected macaques when applied
just 30 min prior to repeated vaginal challenge [5] was similarly
shown to significantly reduce HIV infection in women when used
no more than 12 h before and no less than 12 h after intercourse
[8]. This is a critical step for the field, providing the first proof of
concept that topically applied gels can protect against vaginal HIV
infection. Notably, there is increasing interest in the identification of
microbicide approaches not based on drugs used as first line
therapies against HIV-1 and/or that exhibit cross-resistance, to
limit the emergence of drug resistant viruses. We observed absolute
protection of macaques against vaginal infection for at least 24 h
after daily application of a novel gel comprising a combination of
only 50 mM of the NNRTI MIV-150 with 14 mM zinc acetate
dihydrate. In contrast, gels containing either component alone
afforded only partial protection, with zinc acetate-containing gels
providing significant protection when applied daily or every other
day (even in the absence of MIV-150). Because of this significant
protection, gels with zinc acetate alone should alsobe considered for
furtherdevelopment and human testing, sincethey arenot expected
to promote drug resistance.
Macaque models represent an informative system to evaluate
microbicide candidates before clinical testing [48]. In fact, vaginal
testing of tenofovir gel, using the repeated low dose challenge
model, predicted its activity in humans [5,8]. For greater
stringency, we chose to employ a single high dose challenge of
animals pretreated with DepoProvera, conditions which increase
susceptibility to infection. Our inocula contained 10
3 TCID50
(.1.6610
6 RNA copies), which is at least 100-fold greater than
the median virus RNA levels typical of human semen
[49,50,51,52]. This was combined with applying the gel
repeatedly, an administration regimen aimed not only at
evaluating protection, but also at identifying any adverse reactions
that might augment transmission (since our inoculum was
intended not to infect 100% of the control animals). It is
interesting to note that there was a trend for increased frequency
of infection after repeated application of the placebo MC
compared to single MC dosing (81% versus 56%; p,0.2). This
was not observed with any of the other gels and, in fact, the
infection frequency in the repeated carrageenan vehicle treatment
group was comparable to the single treatment MC group (64%
Table 1. A MIV-150/zinc acetate gel provides significant protection against vaginal SHIV-RT infection.
Gel Not Protected Protected P value vs Carrageenan
Protection vs
Carrageenan
MC ,0.5
Carrageenan
500 mM MIV-150 8 h ,0.4 33%
50 mM MIV-150 8 h ,0.2 56%
50 mM MIV-150 24 h 11 1 %
Zinc acetate 8–24 h ,0.06 67%
MIV-150/zinc acetate 4–24 h ,0.0001 100%
Zinc acetate and MIV-150/zinc acetate, EOD 24 h ,0.06 67%
The protected versus not protected animals in the treatment groups shown in Figure 2 and Figures S1 and S2 are summarized. Each symbol marks an individual animal
as protected or not. The open symbols denote animals with atypical, low-level viral blips (see text). The data for the animals receiving the daily zinc acetate gels have
been pooled since the protection was similar at the two time points (see Table S2). The data for the animals given zinc-containing gels (zinc acetate and MIV-150/zinc
acetate) every other day (EOD) have been pooled since similar protection was observed under this regimen (see Figure 2B). The p values (Fisher’s exact test) for
protection and the percent protection relative to the carrageenan vehicle control group are provided.
doi:10.1371/journal.pone.0015835.t001
the MC and carrageenan controls both represent pooled datasets from different time points (see Table S2). Plasma viral loads were measured over
time, and the data for each animal are shown. The numbers of animals in each treatment group are noted. B. Animals were treated every other day
for 4 weeks with carrageenan gel containing either 14 mM zinc acetate dihydrate or 50 mM MIV-150/14 mM zinc acetate dihydrate, before challenge
with SHIV-RT 24 h later. Viral RNA copies/ml are shown.
doi:10.1371/journal.pone.0015835.g002
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MIV-150/zinc acetate were able to significantly protect against
infection in this rigorous test model.
There are only a few reports on the anti-viral activity of zinc
salts against HIV and other viruses, including HSV-2 [23,24,25].
This is probably largely due to the toxicity often observed in vitro,
which confounds accurate demonstration of anti-viral activity, and
emphasizes the need to evaluate zinc in vivo. A more detailed
analysis of zinc’s mechanism of action is underway to properly
understand the basis for the efficacy of our combination gel. We
recently found that zinc acetate-containing formulations in
carrageenan are extremely effective against vaginal and rectal
HSV-2 infection in mice (Ferna ´ndez-Romero, unpublished),
supporting earlier studies reporting zinc’s anti-herpetic activity
[23,25]. Therefore, in addition to directly preventing the spread of
immunodeficiency viruses as shown here, a zinc-containing gel
might block other STIs like HSV-2 and thereby help reduce HIV
spread indirectly as well. Zinc has been reported to possess
immunomodulatory activities [53], and it is possible that
modifications of the cellular milieu within the mucosal tissues
render the animals resistant to infection. Our initial studies did not
reveal obvious changes in the cytokines and chemokines present in
the vaginal fluids, but further ex vivo infection and immune studies
on biopsies from treated macaques [6] will be useful to dissect the
mechanism of zinc acetate’s anti-viral activity.
On the other hand, MIV-150 has potent anti-viral properties
and may have virucidal activity [13] and, therefore, might act on
viruses in the vaginal cavity prior to their entry into the body, as
well as within the tissues where infection is established and initially
amplified [54]. Pharmacokinetic (PK) studies in rats confirmed
that MIV-150 is absorbed after vaginal application, but detection
in the blood required 10–100 times more MIV-150 than used
herein (Rodriguez, unpublished). These rat studies also showed
that MIV-150 has a short plasma half-life, becoming undetectable
within 24 h. Therefore, it is not surprising that we did not detect
MIV-150 in the plasma after repeated application of gels
containing 50 mM MIV-150, but did detect it in the cervico-
vaginal fluids and associated with the tissues. This is similar to
reports of gels containing the NNRTIs TMC120 or UC-781,
where little or no drug was detected in the blood after repeated
doses of 0.1–10 mg/ml [55,56]. The MIV-150 levels in the swabs
did not predict efficacy, since (i) similar levels were seen 24 h after
the daily versus every other day dosing of MIV-150/zinc acetate,
but the protective effect of MIV-150 was not apparent in the latter
and (ii) while significantly more MIV-150 was present in the swabs
after application of the gel containing 500 mM MIV-150
compared to when the 50 mM MIV-150 gel was applied, the
former was not more effective at preventing infection. Rather, the
level of MIV-150 associated with the cervical tissues appears to be
a better predictor of efficacy. The mean levels of MIV-150
associated with the cervical tissues 8 h after daily treatment with
2m lo f5 0mM MIV-150/14 mM zinc acetate dihydrate (630 pg/
mg of tissue) or 50 mM MIV-150 (240 pg/mg) for 2 weeks are
higher than the levels of TMC120 reportedly associated with the
cervical tissues 8 h after daily treatment for 7 days with 273 mM
TMC120 (3–80 pg/mg) [55]. This might be due to differences in
the formulations that affect the release of the NNRTI and
potentially the association of the drug with the tissues, and/or
specific properties of the NNRTIs.
The few animals that became infected in the presence of MIV-
150 bore virus expressing the wild type RT gene, indicating that
the low doses of MIV-150 used did not select for resistant variants.
Viral stocks were grown for a limited number of in vitro passages, in
the absence of drug selection, and therefore the virus was expected
to be clonal at the time of challenge [21,57]. It is possible that drug
resistance will emerge if an infected individual uses an NNRTI-
containing gel. However, the favorable resistance profile of MIV-
150 and its rapid clearance from the blood, even if it is absorbed
(at undetectable levels) after topical application, should lessen the
pressure on the virus to select escape variants. Macaque studies are
underway to evaluate the emergence of drug resistance during
prolonged treatment of infected animals with MIV-150. Although
there was no impact of tenofovir on drug resistance within the
people who became infected with HIV in the CAPRISA 004 trial
[8], tenofovir is used in current HIV therapies. This ultimately
increases the chances of transmission of tenofovir resistant viruses
(that might develop in HIV-infected people receiving tenofovir
therapy), since they would not be blocked by the tenofovir gel.
Hence, identifying an effective gel containing novel anti-viral
components that are not used in HIV treatment (like MIV-150
and zinc acetate) is critical to also prevent the spread of viruses that
become resistant to current treatments.
Figure 3. MIV-150 does not accumulate systemically after repeated application. Animals were treated with 50 mM MIV-150 (PC-815) or
50 mM MIV-150/14 mM zinc acetate dihydrate (PC-1005) daily for 2 weeks (daily) or with 50 mM MIV-150/14 mM zinc acetate dihydrate every other
day for 4 weeks (EOD). (A) Plasma and vaginal swabs and (B) cervical and vaginal tissues were collected 8 or 24 h after the last gel and the levels of
MIV-150 measured by RIA. The mean concentrations (6SEM, n=6) of MIV-150 for each treatment group are shown.
doi:10.1371/journal.pone.0015835.g003
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comprising two distinct active ingredients: the NNRTI MIV-150
and zinc acetate. The prototype formulation of the MIV-150/zinc
acetate (and MIV-150) gel tested herein contains 1% DMSO and,
while there is no federal regulation or guidance preventing the use
of DMSO in microbicides, the promising MIV-150/zinc acetate
formulation is currently being optimized without DMSO for
human testing. Efficacy at low doses of an NNRTI that is rapidly
cleared if absorbed and not already used to treat HIV is highly
advantageous as it helps reduce cost, the likelihood of drug
resistance, and importantly systemic toxicity. Notably, we
demonstrated complete protection by this combination gel after
daily usage, an effect that lasted for at least 24 h after the last
application. In addition, the significant protective effects of zinc
acetate alone, even when used every other day, is encouraging for
the development of microbicides that are highly unlikely to select
for or induce the development of drug resistant viruses. Safety and
(ultimately) efficacy testing of these formulations in humans is
required before they can be advanced for human use. These
results represent a major step forward for the development of
coitally independent microbicide gels that would be used on a
frequent basis to help stem the spread of HIV and other STIs.
Supporting Information
Figure S1 Limited protection by repeated daily appli-
cation of 500 mM MIV-150. Animals (n=7) were treated daily
for 2 weeks with a carrageenan gel containing 500 mM MIV-150
(PC-817). SHIV-RT was then applied vaginally 8 h after the last
gel. Plasma viral loads were measured over time, and the data for
each animal are shown.
(TIF)
Figure S2 Repeated daily application of MIV-150/zinc
acetate fully protects for 4 h. Animals (n=7) were treated
daily for 2 weeks with a carrageenan gel containing 50 mM MIV-
150 and 14 mM zinc acetate dihydrate (PC-1005). SHIV-RT was
then applied vaginally 4 h after the last gel. Plasma viral loads
were measured over time, and the data for each animal are shown.
(TIF)
Figure S3 Repeated application of MIV-150/zinc ace-
tate does not affect vaginal pH or chemokine responses.
Animals were treated with the indicated gels daily for 14 d.
Vaginal pH was measured (A) prior to vaginal swabs being
collected before gel application (Pre), 1 and 8–9 d during daily gel
application (24 h after the previous gel), and 8 and 24 h after the
last gel was applied (Post). (B) The CXCL8 and CCL2 levels
measured in the vaginal swabs by Luminex are shown. Mean
values 6 SEM are shown in A and B. Baseline (Pre); n=23. MC;
n=2 all time points. Carr; n=6 each time point during treatment,
n=3 each time point post treatment. MIV-150; n=5 1 d and
n=4 9 d during treatment, n=1 8 h and n=3 24 h post
treatment. Zinc acetate; n=5 each time point during treatment,
n=2 8 h and n=3 24 h post treatment. MIV-150/zinc acetate;
n=5 each time point during treatment, n=2 8 h and n=3 24 h
post treatment. Samples were taken on day 8 during treatment
with MC or zinc acetate, while all others were taken on day 9
during the various treatments.
(TIF)
Figure S4 MIV-150 levels after daily application of
500 mM MIV-150. Animals (n=6) were treated daily for 2
weeks with a carrageenan gel containing 500 mM MIV-150.
Blood, vaginal swabs, and vaginal and cervical biopsies were
collected 8 h after the last gel was applied. MIV-150 levels were
measured by RIA and mean values 6 SEM are shown for each.
(TIF)
Table S1 Infection and immune status of SHIV-RT-
challenged macaques after single gel dosing.
(DOC)
Table S2 Infection and immune status of SHIV-RT-
challenged macaques after daily gel application.
(DOC)
Table S3 Infection and immune status of SHIV-RT-
challenged macaques after gel application every other
day.
(DOC)
Table S4 MIV-150 does not select for infection by RT
mutant virus.
(DOC)
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